FDA granted rare pediatric disease designation to investigational (Z)-endoxifen for McCune-Albright syndrome in girls.
The FDA has granted rare pediatric disease designation to investigational oral (Z)-endoxifen for the treatment of McCune-Albright syndrome (MAS) in females, according to an Atossa Therapeutics announcement.1 The designation does not constitute drug approval, but it may make the sponsor eligible for a priority review voucher if a future marketing application for this indication is approved.2
For clinicians caring for children with MAS, the update is notable because gonadotropin-independent precocious puberty in girls remains a difficult-to-manage manifestation of the disorder, with limited evidence-based medical options and variable long-term control of growth and skeletal outcomes.3 In a company statement, Steven Quay, MD, PhD, president and CEO of Atossa, called the designation “an important regulatory milestone” and said MAS carries “significant unmet medical need.”1
MAS is a rare mosaic disorder caused by postzygotic activating variants in GNAS and classically associated with fibrous dysplasia, café-au-lait macules, and hyperfunctioning endocrinopathies.3,4 In girls, recurrent autonomous ovarian estrogen production can drive episodic vaginal bleeding, breast development, accelerated growth velocity, advanced bone age, and compromised adult height potential.3 Current treatment is generally individualized and aimed at suppressing peripheral estrogen effects rather than the hypothalamic-pituitary-gonadal axis.
The FDA’s rare pediatric disease program applies to serious or life-threatening conditions that primarily affect patients younger than 18 years and meet criteria as rare diseases.2 If a drug with this designation is later approved for the qualifying indication, the sponsor may receive a transferable priority review voucher. The designation itself does not provide evidence of efficacy or safety, and no phase 2 or phase 3 MAS data for (Z)-endoxifen were included in the company release.1
Atossa described (Z)-endoxifen as a selective estrogen receptor modulator/degrader under development in oncology and rare diseases.1 Endoxifen is the major active metabolite of tamoxifen, but investigational direct formulations are being studied to avoid dependence on CYP2D6-mediated metabolism and to achieve more predictable exposure. Published early-phase clinical work with oral endoxifen has largely been in breast cancer settings rather than pediatric endocrinology.4 No FDA-approved indication currently exists for (Z)-endoxifen, and the company said the agent remains investigational.
Clinically, the rationale for studying an estrogen receptor–targeting agent in MAS is plausible because estrogen excess is a central driver of precocious puberty in affected girls. However, the treatment landscape has been mixed. International expert guidance and observational literature describe the use of aromatase inhibitors and selective estrogen receptor modulators, but responses have varied, and data are limited by small cohorts, off-label use, and a lack of robust comparative trials. These factors have left ongoing uncertainty about optimal sequencing, durability of benefit, and effects on final height and skeletal maturation.3
That context makes the regulatory designation more of a development signal than a practice-changing event. Janet Rea, senior vice president of research and development at Atossa, said in the release that the company is “further defin[ing] the clinical development path” for MAS.1 No trial identifier, planned study design, enrollment target, or timeline was disclosed.
Important unanswered questions remain before clinicians can assess whether (Z)-endoxifen could fit into MAS care. These include the magnitude of effect on bleeding frequency, bone age advancement, growth velocity, and predicted adult height; the durability of suppression of estrogenic symptoms; and the safety profile with prolonged use in children, including bone, gynecologic, and thromboembolic considerations. Because MAS is heterogeneous and rare, future studies will likely face enrollment and endpoint-selection challenges.3
Atossa also noted that the company has previously received orphan drug designation and rare pediatric disease designation for (Z)-endoxifen in Duchenne muscular dystrophy, underscoring the sponsor’s broader effort to expand the compound beyond oncology.1 For now, though, the FDA action is limited to designation status for MAS in females and should be interpreted as an early regulatory step rather than evidence supporting clinical use.
